Leyden Laboratories BV, a biotech company from the Netherlands, has secured €20 million in venture debt financing from the European Investment Bank (EIB) to advance its antibody programs designed to combat viral infections. The primary focus is on its lead product, PanFlu, a nasal spray that targets influenza viruses, including Avian Flu, and aims to bolster pandemic preparedness. This funding aligns with the European Commission's InvestEU initiative, emphasizing the EU's commitment to enhancing health security and readiness against potential health crises, following lessons learned from the COVID-19 pandemic.
The COVID-19 pandemic taught us multiple lessons, including that we should strengthen the EU's preparedness and autonomy in key areas like bio sciences.
Respiratory viruses are common and affect us all, especially during pandemic and seasonal outbreaks, highlighting the necessity for innovative solutions to enhance our defenses.
Collection
[
|
...
]